Nasdaq · Healthcare
Connect Biopharma Holdings Ltd (CNTB)
As-reported financials and recent SEC filings for Connect Biopharma Holdings Ltd, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$64,000
Net income
$-55.5M
Net margin
—
Diluted EPS
$-1.00
ROE
-132.2%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $64,000 | $26.0M | $0 | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-58.1M | $-22.5M | $-69.1M | — | — |
| Net income | $-55.5M | $-15.6M | $-62.1M | — | — |
| Diluted EPS | $-1.00 | $-0.28 | $-1.13 | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-01
View on EDGAR →42026-07-01
View on EDGAR →42026-06-02
View on EDGAR →EFFECT2026-06-01
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →F-32026-05-15
View on EDGAR →10-Q2026-05-12
View on EDGAR →8-K2026-05-12
View on EDGAR →Largest Healthcare peers
Go deeper on CNTB
Search Connect Biopharma Holdings Ltd’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.